General Drug Manufacturer Stocks
16 US-listed general drug manufacturer companies above our tradable floor ($5 and $1 million a day), largest first, with each one's stage, price and valuation after the close.
16
companies
9 (56%)
in a Stage 2 uptrend
+16.8%
3-month return, weighted by size
1 · 1 · 5
in Stage 1 · 3 · 4
Only the Stage 2 ones →Filter them in the screener →All Health Care stocks →Industry rotation →
Every general drug manufacturer stock we cover
| Stock | Stage | Close | Day | 3 months | From high | RS | P/E | Yield | Market cap |
|---|---|---|---|---|---|---|---|---|---|
| LLYEli Lilly | Stage 2, wk 2 | $1,417.54 | +3.2% | +26.6% | 0.0% | 92 | 43.9 | 0.54% | $1.26T |
| JNJJohnson & Johnson | Stage 2, wk 17 | $273.20 | -0.7% | +7.9% | -1.9% | 86 | 40.6 | 2.08% | $658B |
| ABBVAbbVie | Stage 2, wk 17 | $294.89 | +1.4% | +21.1% | 0.0% | 79 | 80.6 | 2.43% | $521B |
| MRKMerck | Stage 2, wk 18 | $149.52 | +2.2% | +17.7% | -3.9% | 92 | 116.9 | 2.27% | $369B |
| NVSNovartis | Stage 4, wk 4 | $160.79 | -0.2% | +4.6% | -1.7% | 79 | 23.6 | 3.08% | $304B |
| AZNAstraZeneca | Stage 1, wk 1 | $186.65 | +7.0% | +18.2% | -10.5% | 65 | 25.8 | 1.90% | $289B |
| AMGNAmgen | Stage 2, wk 17 | $466.01 | +1.1% | +23.7% | 0.0% | 90 | 27.9 | 2.30% | $252B |
| GILDGilead Sciences | Stage 2, wk 10 | $170.68 | +3.1% | +30.9% | 0.0% | 85 | — | 2.14% | $212B |
| NVONovo Nordisk | Stage 4, wk 5 | $40.00 | +2.2% | -14.0% | -34.4% | 40 | 9.6 | 4.60% | $176B |
| PFEPfizer | Stage 2, wk 10 | $30.52 | +1.9% | +21.9% | 0.0% | 78 | 40.0 | 5.76% | $174B |
| BMYBristol-Myers Squibb | Stage 3, wk 3 | $62.48 | +1.8% | -3.6% | -7.3% | 87 | 13.9 | 4.12% | $128B |
| SNYSanofi | Stage 4, wk 5 | $44.34 | +2.8% | +3.2% | -10.6% | 48 | 22.1 | 5.90% | $106B |
| GSKGSK | Stage 4, wk 8 | $49.51 | +1.7% | -3.0% | -16.9% | 62 | 16.2 | 3.63% | $99.2B |
| BIIBBiogen | Stage 2, wk 22 | $253.62 | +1.6% | +25.7% | -0.1% | 91 | 45.1 | — | $37.5B |
| GRFSGrifols | Stage 4, wk 4 | $8.10 | +0.7% | +3.1% | -15.5% | 44 | 9.7 | 1.41% | $5.5B |
| OGNOrganon | Stage 2, wk 24 | $13.84 | +0.2% | +2.2% | 0.0% | 96 | 17.6 | 0.58% | $3.6B |
General Drug Manufacturer Stocks: quick answers
How many general drug manufacturer stocks are in an uptrend?
As of Oct 30, 2026, 9 of the 16 US-listed general drug manufacturer stocks we cover are in Stage 2, the uptrend phase, including Eli Lilly (LLY), Johnson & Johnson (JNJ), AbbVie (ABBV), Merck (MRK) and Amgen (AMGN).
What is the largest general drug manufacturer stock?
Eli Lilly (LLY), with a market value of $1.26T. It closed at $1,417.54 on Oct 30, 2026, in Stage 2.
Which general drug manufacturer stocks are near their 52-week high?
As of Oct 30, 2026, 6 are within 5% of a 52-week high: Eli Lilly (LLY), Johnson & Johnson (JNJ), AbbVie (ABBV), Merck (MRK), Novartis (NVS) and Amgen (AMGN).
End-of-day data for common stocks and ADRs on the NYSE, Nasdaq and NYSE American, computed after each US close and dated to the trading session.